Publicaciones en colaboración con investigadores/as de Corporació Sanitària Parc Taulí (7)

2019

  1. Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program

    Clinical and Translational Oncology, Vol. 21, Núm. 9, pp. 1270-1279

2016

  1. SEOM Clinical Guideline in ovarian cancer (2016)

    Clinical and Translational Oncology, Vol. 18, Núm. 12, pp. 1206-1212

2014

  1. Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours

    Clinical and Translational Oncology, Vol. 16, Núm. 3, pp. 322-329

2013

  1. Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC)

    Clinical and Translational Oncology, Vol. 15, Núm. 9, pp. 698-704

2011

  1. Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients A GEICO study

    International Journal of Gynecological Cancer, Vol. 21, Núm. 6, pp. 1048-1055

  2. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: Baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity

    Annals of Oncology, Vol. 22, Núm. 12, pp. 2646-2653

2008

  1. A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia

    Current Medical Research and Opinion, Vol. 24, Núm. 10, pp. 2931-2942